(0.37%) 5 110.25 points
(0.79%) 38 684 points
(0.64%) 17 763 points
(0.28%) $79.17
(-0.15%) $2.03
(-0.03%) $2 308.90
(-0.16%) $26.79
(1.18%) $974.00
(-0.13%) $0.931
(-0.65%) $10.92
(-0.18%) $0.796
(0.50%) $91.59
5 days till quarter result
(amc 2024-05-08)
Expected move: +/- 6.31%
@ $4.14
Utstedt: 14 feb 2024 @ 15:30
Avkastning: 13.04%
Forrige signal: feb 12 - 20:00
Forrige signal:
Avkastning: -5.91 %
Live Chart Being Loaded With Signals
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs...
Stats | |
---|---|
Dagens volum | 840 218 |
Gjennomsnittsvolum | 2.40M |
Markedsverdi | 272.37M |
EPS | $0 ( 2024-05-01 ) |
Neste inntjeningsdato | ( $0.0500 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 117.00 |
ATR14 | $0.00500 (0.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-04 | Williams Timothy | Sell | 8 147 | Common Stock |
2024-03-05 | Williams Timothy | Sell | 8 941 | Common Stock |
2024-03-04 | Wijkstrom Joakim | Sell | 7 498 | Common Stock |
2024-03-05 | Wijkstrom Joakim | Sell | 9 229 | Common Stock |
2024-03-04 | Polymeropoulos Mihael Hristos | Sell | 30 884 | Common Stock |
INSIDER POWER |
---|
66.80 |
Last 99 transactions |
Buy: 3 050 635 | Sell: 650 292 |
Volum Korrelasjon
Vanda Pharmaceuticals Inc Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
GOSS | 0.944 |
THTX | 0.944 |
PTPI | 0.938 |
VORB | 0.931 |
TRVN | 0.929 |
LQDT | 0.929 |
TIVC | 0.928 |
XFOR | 0.927 |
SIGA | 0.925 |
CREG | 0.922 |
10 Mest negative korrelasjoner | |
---|---|
RXDX | -0.952 |
AUPH | -0.951 |
POWL | -0.932 |
EZGO | -0.932 |
AVAC | -0.93 |
SUMR | -0.929 |
ALXN | -0.924 |
EMLD | -0.921 |
TCMD | -0.92 |
AVEO | -0.919 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Vanda Pharmaceuticals Inc Korrelasjon - Valuta/Råvare
Vanda Pharmaceuticals Inc Økonomi
Annual | 2023 |
Omsetning: | $192.64M |
Bruttogevinst: | $175.75M (91.23 %) |
EPS: | $0.0437 |
FY | 2023 |
Omsetning: | $192.64M |
Bruttogevinst: | $175.75M (91.23 %) |
EPS: | $0.0437 |
FY | 2022 |
Omsetning: | $254.38M |
Bruttogevinst: | $230.10M (90.45 %) |
EPS: | $0.110 |
FY | 2021 |
Omsetning: | $268.68M |
Bruttogevinst: | $243.05M (90.46 %) |
EPS: | $0.610 |
Financial Reports:
No articles found.
Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.